Pharmacokinetics and Safety of Momelotinib in Subjects With Hepatic or Renal Impairment.

Author: KawashimaJun, KwanEllen, SilvermanJeffrey A, TarnowskiThomas, WengWinnie, XinYan

Paper Details 
Original Abstract of the Article :
Momelotinib is a Janus kinase 1/2 inhibitor in clinical development for the treatment of myelofibrosis. Two phase 1 open-label, parallel-group, adaptive studies were conducted to evaluate the pharmacokinetics of a single 200-mg oral dose of momelotinib in subjects with hepatic or renal impairment co...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元:
https://doi.org/10.1002/jcph.1050

データ提供:米国国立医学図書館(NLM)

Momelotinib: Pharmacokinetics and Safety in Hepatic and Renal Impairment

The development of medications, especially those targeting specific diseases, requires a thorough understanding of how these medications interact with the body. This study investigates the pharmacokinetics and safety of momelotinib, a Janus kinase 1/2 inhibitor in clinical development for the treatment of myelofibrosis, in patients with impaired liver or kidney function. This research, like a desert expedition studying the effects of different water sources on plant life, delves into the intricacies of drug metabolism in patients with compromised organ function.

Momelotinib: Dose Adjustment Based on Hepatic and Renal Function

The study demonstrates that dose adjustment of momelotinib is not necessary for patients with mild to moderate hepatic or renal impairment. However, in patients with severe hepatic impairment, the dose should be reduced. This research, like a wise desert traveler adapting their journey to the changing landscape, provides essential information for optimizing momelotinib treatment and ensuring patient safety.

Momelotinib: A Tailored Approach to Treatment for Myelofibrosis

This study underscores the importance of individualized treatment for myelofibrosis, taking into account the patient's liver and kidney function. By understanding the pharmacokinetics and safety of momelotinib in patients with varying levels of hepatic and renal impairment, healthcare providers can tailor treatment to meet the specific needs of each patient, ensuring optimal outcomes and minimizing potential risks. This research, like a skilled desert guide, provides valuable insights for navigating the complexities of myelofibrosis treatment and optimizing patient care.

Dr.Camel's Conclusion

This study provides valuable insights into the pharmacokinetics and safety of momelotinib in patients with hepatic and renal impairment, guiding clinicians in adjusting treatment regimens to ensure optimal outcomes and patient safety. The research underscores the importance of individualized medicine, tailoring treatment strategies to meet the specific needs of each patient.

Date :
  1. Date Completed 2019-05-03
  2. Date Revised 2019-05-03
Further Info :

Pubmed ID

29283448

DOI: Digital Object Identifier

10.1002/jcph.1050

Related Literature

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.